Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the entry of LAMAs (e.g., BI’s Spiriva) and novel biologics (e.g., AstraZeneca’s Fasenra, Teva’s Cinqair, Sanofi / Regeneron’s Dupixent, GSK’s Nucala) in the market, an unmet need remains for effective therapies for severe disease, especially for patients whose symptoms are not adequately controlled with current therapies or who depend on frequent SABA and/or oral corticosteroid use to achieve relief. This “Unmet Need” report provides quantitative insights into key treatment drivers and goals and the current level of unmet need in severe asthma, based on the perceptions of U.S. and European physicians. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.
- What are the treatment drivers and goals for severe asthma?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current inhaled (e.g., Spiriva) and biological (e.g., Dupixent, Nucala) therapies perform on key treatment drivers and goals in severe asthma?
- What are the prevailing areas of unmet need and opportunity in severe asthma?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European physicians for a hypothetical new drug targeting severe asthma?
United States, France, Germany, United Kingdom
Survey of approximately 30 U.S. pulmonologists, 30 U.S. allergists, and 30 European pulmonologists
Key Drugs Covered
Xolair, Nucala, Cinqair / Cinqaero, Fasenra, Dupixent, Spiriva (tiotropium), LABA / ICSFDCs
Key metrics included
- Target Product Profile (TPP) simulator based on conjoint analysis methodology.
- Stated versus derived importance of product attributes on prescribing behavior.
- Assessment of current drug performance against treatment drivers and goals.
- Physician perceptions of unmet needs in the indication and related indications.
- Analysis of remaining drug development opportunities.
“Unmet Need” supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
- Asthma - Unmet Need - Detailed, Expanded Analysis (Severe Asthma)
Author(s): Ritesh Gupta, PhD
Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease.
He holds a Ph.D. degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.